和血明目片联合胰激肽原酶肠溶片治疗糖尿病视网膜病变的疗效观察

目的探究和血明目片联合胰激肽原酶肠溶片治疗糖尿病视网膜病变的临床效果。方法选取济南市济钢医院2016年5月—2017年5月收治的糖尿病视网膜病变患者200例,随机分成对照组(100例)和治疗组(100例)。对照组患者口服胰激肽原酶肠溶片,1片/次,3次/d;治疗组患者在对照组基础上口服和血明目片,5片/次,3次/d。两组患者均连续治疗3个月。观察两组患者临床疗效,同时比较治疗前后两组患者眼底情况、血浆黏度和视网膜中央动脉阻力指数(RI)水平。结果治疗后,对照组和治疗组临床有效率分别为86.26%、94.74%,两组比较差异有统计学意义(P0.05)。治疗后,两组患者眼底出血灶面积、黄斑厚度及血管瘤体积均显著降低(P0.05),且治疗组各指标均明显优于对照组P0.05)。治疗后,两组患者血浆黏度和视网膜中央动脉RI水平显著降低(P0.05),且治疗组血浆黏度和RI水平明显低于对照组(P0.05)。结论和血明目片联合胰激肽原酶肠溶片治疗糖尿病视网膜病变可显著改善患者眼底出血和眼部动脉血流动力学,且安全性好。

Clinical observation of Hexue Mingmu Tablets combined with Pancreatic Kininogenase Enteric-coated Tablets in treatment of diabetic retinopathy

Objective To explore the clinical effect of Hexue Mingmu Tablets combined with Pancreatic Kininogenase Enteric-coated Tablets in treatment of diabetic retinopathy. Methods Patients (200 cases) with diabetic retinopathy in Ji''nan Jigang Hospital from May 2016 to May 2017 were randomly divided into control (100 cases) and treatment (100 cases) groups. Patients in the control group were po administered with Pancreatic Kininogenase Enteric-coated Tablets, 1 tablet/time, three times daily. Patients in the treatment group were po administered with Hexue Mingmu Tablets on the basis of the control group, 5 tablets/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacy was evaluated, and the fundus status, the plasma viscosity and RI levels of arteriae centralis retinae in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups was 86.26% and 94.74% respectively, and there were differences between two groups (P<0.05). After treatment, the fundus hemorrhage area, macular thickness and hemangioma volume in two groups were significantly decreased (P<0.05), and these indexes in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the plasma viscosity and RI levels of arteriae centralis retinae in two groups were significantly decreased (P<0.05), and the plasma viscosity and RI levels in the treatment group were significantly lower than those in the control group (P<0.05). Conclusion Hexue Mingmu Tablets combined with Pancreatic Kininogenase Enteric-coated Tablets in treatment of diabetic retinopathy can improve the ocular fundus bleeding and ocular arterial hemodynamics with high safety.